JP2019507111A - 代謝抵抗性フェンフルラミン類縁体およびその使用法 - Google Patents
代謝抵抗性フェンフルラミン類縁体およびその使用法 Download PDFInfo
- Publication number
- JP2019507111A JP2019507111A JP2018532741A JP2018532741A JP2019507111A JP 2019507111 A JP2019507111 A JP 2019507111A JP 2018532741 A JP2018532741 A JP 2018532741A JP 2018532741 A JP2018532741 A JP 2018532741A JP 2019507111 A JP2019507111 A JP 2019507111A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- formula
- aryl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(*)(*)N(*)C1(*)C(*)(*I)c2cc(*)ccc2C1(*)* Chemical compound *C(*)(*)N(*)C1(*)C(*)(*I)c2cc(*)ccc2C1(*)* 0.000 description 7
- OXOBKZZXZVFOBB-UHFFFAOYSA-N C(C1)CNC1C(c1ccccc1)c1ccccc1 Chemical compound C(C1)CNC1C(c1ccccc1)c1ccccc1 OXOBKZZXZVFOBB-UHFFFAOYSA-N 0.000 description 1
- RWTNXJXZVGHMGI-UHFFFAOYSA-N C1CC(C(c2ccccc2)c2ccccc2)NCC1 Chemical compound C1CC(C(c2ccccc2)c2ccccc2)NCC1 RWTNXJXZVGHMGI-UHFFFAOYSA-N 0.000 description 1
- MUCGWXLYVIUWGS-UHFFFAOYSA-N CC(Cc1cc(C(F)(F)F)ccc1)NC(C(F)(F)F)(F)F Chemical compound CC(Cc1cc(C(F)(F)F)ccc1)NC(C(F)(F)F)(F)F MUCGWXLYVIUWGS-UHFFFAOYSA-N 0.000 description 1
- XGVGRJLWFJDRPN-UHFFFAOYSA-N CC(Cc1cc(C(F)(F)F)ccc1)NC(C(F)(F)F)F Chemical compound CC(Cc1cc(C(F)(F)F)ccc1)NC(C(F)(F)F)F XGVGRJLWFJDRPN-UHFFFAOYSA-N 0.000 description 1
- VWFTXBQOXGEASH-UHFFFAOYSA-N CC(Cc1cc(C(F)(F)F)ccc1)NCCF Chemical compound CC(Cc1cc(C(F)(F)F)ccc1)NCCF VWFTXBQOXGEASH-UHFFFAOYSA-N 0.000 description 1
- XSWHNYGMWWVAIE-UHFFFAOYSA-N OC(C1NCCCC1)(c1ccccc1)c1ccccc1 Chemical compound OC(C1NCCCC1)(c1ccccc1)c1ccccc1 XSWHNYGMWWVAIE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271168P | 2015-12-22 | 2015-12-22 | |
| US62/271,168 | 2015-12-22 | ||
| PCT/US2016/067852 WO2017112701A1 (en) | 2015-12-22 | 2016-12-20 | Metabolism resistant fenfluramine analogs and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019507111A true JP2019507111A (ja) | 2019-03-14 |
| JP2019507111A5 JP2019507111A5 (enExample) | 2020-01-30 |
Family
ID=59065966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532741A Pending JP2019507111A (ja) | 2015-12-22 | 2016-12-20 | 代謝抵抗性フェンフルラミン類縁体およびその使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20170174614A1 (enExample) |
| EP (1) | EP3393470B1 (enExample) |
| JP (1) | JP2019507111A (enExample) |
| KR (1) | KR20180095674A (enExample) |
| AU (1) | AU2016379345B2 (enExample) |
| CA (1) | CA3007673A1 (enExample) |
| WO (1) | WO2017112701A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| JP2019507111A (ja) | 2015-12-22 | 2019-03-14 | ゾゲニクス インターナショナル リミテッド | 代謝抵抗性フェンフルラミン類縁体およびその使用法 |
| KR102688278B1 (ko) | 2015-12-22 | 2024-07-26 | 조게닉스 인터내셔널 리미티드 | 펜플루라민 조성물 및 그 제조 방법 |
| CA3032996C (en) | 2016-08-24 | 2025-05-06 | Zogenix International Ltd | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| AU2019384963B2 (en) | 2018-11-19 | 2022-05-26 | Zogenix International Limited | Methods of treating Rett syndrome using fenfluramine |
| EP3931178B1 (en) * | 2019-03-01 | 2025-06-25 | Abrexa Pharmaceuticals, Inc. | Compounds for prevention and treatment of post-operative cognitive dysfunction |
| WO2020180821A1 (en) * | 2019-03-01 | 2020-09-10 | Abrexa Pharmaceuticals, Inc. | Compounds for prevention and treatment of obesity and related disorders |
| US20220226508A1 (en) * | 2019-05-29 | 2022-07-21 | The Regents Of The University Of California | Methods and compositions for treating epilepsy |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| EP4392027A4 (en) | 2021-08-23 | 2025-07-23 | Alexander Shulgin Res Institute Inc | FLUORINATED EMPATHOGENS |
| WO2023101866A1 (en) * | 2021-12-01 | 2023-06-08 | Zogenix International Limited | Fenfluramine for treatment of conditions associated with spreading depolarization |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3117160A (en) * | 1961-07-27 | 1964-01-07 | Pfizer & Co C | Aralkylamines |
| GB1399015A (en) * | 1971-08-28 | 1975-06-25 | Degussa | Fluoroalkylated phenylethylamine derivatives |
| JPH09501429A (ja) * | 1993-08-06 | 1997-02-10 | ジ・アップジョン・カンパニー | 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類 |
| JPH10501230A (ja) * | 1994-05-27 | 1998-02-03 | シンテックス（ユー・エス・エイ）インコーポレイテッド | １−ブチル−２−［２’−（２ｈ−テトラゾル−５−イル）−ビフェニル−４−イルメチル］−１ｈ−インドール−３−カルボン酸の製法 |
| WO2007073503A2 (en) * | 2005-12-21 | 2007-06-28 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| US20140142140A1 (en) * | 2011-07-08 | 2014-05-22 | Gosforth Centre (Holdings) Pty Ltd | Pharmaceutical composition for neurological disorders |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR104F (enExample) | 1960-11-05 | |||
| US3198834A (en) | 1964-07-27 | 1965-08-03 | Snc Science Union Et Compagnie | Optical isomers of trifluoromethylated phenethylamines |
| GB1254332A (en) * | 1969-02-27 | 1971-11-17 | Science Union & Cie | Amino acids and their derivatives and processes for preparing them |
| DE2150399A1 (de) | 1971-10-09 | 1973-04-12 | Hoechst Ag | Neue oxime |
| GB1413078A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof |
| GB1413070A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of - norfenfluramine and - fenfluramine and salts thereof |
| US4309445A (en) | 1980-06-16 | 1982-01-05 | Massachusetts Institute Of Technology | d-Fenfluramine for modifying feeding behavior |
| US4452815A (en) | 1980-06-16 | 1984-06-05 | Massachusetts Institute Of Technology | Method of utilizing d,l-fenfluramine for modifying feeding behavior |
| DE3717434C1 (de) | 1987-05-23 | 1988-09-15 | Degussa | Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril |
| KR890003368A (ko) | 1987-08-06 | 1989-04-14 | 원본미기재 | 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법 |
| US4857553A (en) | 1987-08-06 | 1989-08-15 | A. H. Robins Company, Incorporated | Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents |
| HU204497B (en) | 1989-10-09 | 1992-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing phenfluramine |
| IT1238686B (it) | 1990-02-09 | 1993-09-01 | Lab Mag Spa | Procedimento per la preparazione di levo e destro fenfluramina |
| FR2684552B1 (fr) | 1991-12-06 | 1995-04-28 | Adir | Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants. |
| US5985880A (en) | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
| DK0762877T3 (da) * | 1994-06-03 | 2001-07-16 | Thejmde Trust | Meta-substituerede arylalkylaminer og terapeutiske og diagnostiske anvendelser deraf |
| IT1298349B1 (it) | 1996-05-29 | 2000-01-05 | Alfa Chem Ital | Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina |
| IT1292885B1 (it) | 1997-04-28 | 1999-02-11 | Alfa Chem Ital | Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina. |
| EP0920864A1 (en) | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| US20020098175A1 (en) | 1998-06-16 | 2002-07-25 | Zohoungbogbo Mathias C. | Dietetic food composition and dietetic method using such composition |
| US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| JP4374441B2 (ja) | 1998-12-23 | 2009-12-02 | ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー | 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤 |
| US20080103179A1 (en) | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| US7124031B1 (en) | 2000-05-11 | 2006-10-17 | Medco Health Solutions, Inc. | System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records |
| WO2002006826A1 (en) | 2000-07-17 | 2002-01-24 | Opt-E-Scrip, Inc. | Single-patient drug trials used with accumulated database |
| US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| WO2003000047A2 (en) | 2001-06-22 | 2003-01-03 | Universite Catholique De Louvaine | Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids |
| EP1411955A4 (en) | 2001-07-31 | 2006-07-05 | Wyeth Corp | SUCRALOSE FORMULATIONS FOR COVERING UNANGEAN TASTE |
| AUPR732601A0 (en) | 2001-08-28 | 2001-09-20 | Polychip Pharmaceuticals Pty Ltd | Methods for the synthesis of amines such as ephedrine and inter mediates |
| RU2317104C2 (ru) | 2001-09-24 | 2008-02-20 | Импиэриэл Инноувейшнс Лимитид | Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения |
| NZ532427A (en) | 2001-09-24 | 2008-07-31 | Imp Innovations Ltd | Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y) |
| US6599901B1 (en) | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| US7101572B2 (en) | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| US7668730B2 (en) | 2002-12-17 | 2010-02-23 | JPI Commercial, LLC. | Sensitive drug distribution system and method |
| WO2005004865A1 (en) | 2003-07-08 | 2005-01-20 | Georg-August-Universität Göttingen | Use of 5-ht4(a)-serotonin receptor agonists |
| GB0410266D0 (en) | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
| US20050260610A1 (en) | 2004-05-20 | 2005-11-24 | Kurtz Richard E | Method for diagnosing and prescribing a regimen of therapy for human health risk |
| US9820658B2 (en) | 2006-06-30 | 2017-11-21 | Bao Q. Tran | Systems and methods for providing interoperability among healthcare devices |
| AU2006225980A1 (en) | 2005-03-21 | 2006-09-28 | Health-Smart Limited | System for continuous blood pressure monitoring |
| JP2008542237A (ja) | 2005-05-25 | 2008-11-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トピラメートの小児科用製剤 |
| NZ564892A (en) | 2005-06-16 | 2011-10-28 | Bionomics Ltd | Methods of treatment, and diagnosis of epilepsy by detecting a D674G mutation in the SCN1A gene |
| GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| US9125900B2 (en) | 2005-09-14 | 2015-09-08 | University Of The Witwatersrand, Johannesburg | Pharmaceutical composition |
| EP1926427A4 (en) | 2005-09-19 | 2012-06-06 | Biolert Ltd | DEVICE AND METHOD FOR DETECTING AN EPILEPTIC EVENT |
| CA2911569C (en) | 2005-11-29 | 2019-11-26 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
| WO2007079181A2 (en) | 2005-12-28 | 2007-07-12 | Neurovista Corporation | Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders |
| KR20080091473A (ko) | 2006-02-06 | 2008-10-13 | 노파르티스 아게 | 유기 화합물들의 조합물 |
| DE102006030113B4 (de) | 2006-06-28 | 2009-02-12 | Chemische Fabrik Budenheim Kg | Graphitfreier Hochtemperatur-Schmierstoff |
| EP2061471A4 (en) | 2006-08-31 | 2012-02-01 | Univ Alberta | PROCESS FOR INHIBITING RESTRICTED DEPRESSION WITH POSITIVE ALLOSTER AMPA RECEPTOR MODULATORS |
| WO2008095095A2 (en) | 2007-01-31 | 2008-08-07 | Quintiles Transnational Corp. | Methods and systems for allocating representatives to sites in clinical trials |
| WO2008096271A2 (en) | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
| JP2010520162A (ja) | 2007-02-28 | 2010-06-10 | スミスクライン ビーチャム コーポレーション | ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体 |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| WO2010020585A1 (en) | 2008-08-18 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin reuptake inhibitors for the treatment of rett syndrome |
| KR101851120B1 (ko) | 2008-09-05 | 2018-04-23 | 그뤼넨탈 게엠베하 | 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물 |
| US8386274B1 (en) | 2008-09-17 | 2013-02-26 | Mckesson Financial Holdings Limited | Systems and methods for a prescription safety network utilizing eligibility verification transactions |
| JP2012505172A (ja) | 2008-10-09 | 2012-03-01 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | パラセタモールを有する液体医薬製剤 |
| US20110230473A1 (en) | 2008-10-10 | 2011-09-22 | Gordon Richard K | Methods and Compositions for Treating Status Epilepticus and Seizures Causing Status Epilepticus |
| TWI503101B (zh) | 2008-12-15 | 2015-10-11 | Proteus Digital Health Inc | 與身體有關的接收器及其方法 |
| US20120065999A1 (en) | 2009-03-09 | 2012-03-15 | Celgene Corporation | Device for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May Be Contraindicated and Methods for Use Thereof |
| EP2419400A1 (en) | 2009-04-15 | 2012-02-22 | Research Triangle Institute | Monoamine reuptake inhibitors |
| WO2010124137A1 (en) | 2009-04-22 | 2010-10-28 | Millennium Pharmacy Systems, Inc. | Pharmacy management and administration with bedside real-time medical event data collection |
| US9453027B2 (en) | 2009-07-27 | 2016-09-27 | Daljit Singh Dhanoa | Deuterium-enriched pyridinonecarboxamides and derivatives |
| AR079862A1 (es) | 2010-01-08 | 2012-02-22 | Eurand Inc | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion |
| JP5890328B2 (ja) | 2010-03-09 | 2016-03-22 | パーセプティメッド インコーポレイテッドＰｅｒｃｅｐｔｉｍｅｄ， Ｉｎｃ． | 薬剤の検証及び供給 |
| WO2011119227A2 (en) | 2010-03-25 | 2011-09-29 | Columbia Northwest Pharmaceuticals, Llc | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients |
| JP2011221623A (ja) | 2010-04-06 | 2011-11-04 | Kakimori Suri | 在宅診療支援システム及び方法 |
| AU2011255276B2 (en) | 2010-05-21 | 2016-09-22 | Research Triangle Institute | Phenylmorpholines and analogues thereof |
| EP2399513B1 (en) | 2010-06-23 | 2017-01-04 | Qatar University Qstp-B | System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms |
| EP2598159A4 (en) | 2010-07-30 | 2014-01-08 | Merck Sharp & Dohme | INHIBITION OF THE CYP3A DRUG MIXTURE EXCHANGE |
| EP3485878A1 (en) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| US20120270848A1 (en) | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
| CA2814230A1 (en) | 2010-10-26 | 2012-05-03 | Alpharma Pharmaceuticals, Llc | Formulations and methods for attenuating respiratory depression induced by opioid overdose |
| RU103209U1 (ru) | 2010-10-29 | 2011-03-27 | Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" | Клиническая информационная система |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| JP5693325B2 (ja) | 2011-03-29 | 2015-04-01 | 小林クリエイト株式会社 | 健診結果出力システム及び健診結果出力プログラム |
| US20140348966A1 (en) | 2011-12-22 | 2014-11-27 | Onesmo B. Balemba | Garcinia buchananii baker compounds, compositions and related methods |
| WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| US20130218586A1 (en) | 2012-02-21 | 2013-08-22 | Frederic J. Huser | Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status |
| JP6075973B2 (ja) | 2012-06-04 | 2017-02-08 | 富士通株式会社 | 健康状態判定装置およびその作動方法 |
| CA2891342A1 (en) | 2012-11-15 | 2014-05-22 | Galleon Pharmaceuticals, Inc. | Novel orally bioavailable breathing control modulating compounds, and methods of using same |
| WO2014106825A2 (en) | 2013-01-06 | 2014-07-10 | Jonathan Rabinowitz | Methods and devices for identifying improper medical reporting |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| ES2813450T3 (es) | 2013-08-19 | 2021-03-23 | Univ California | Compuestos y métodos para tratar un trastorno epiléptico |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| US20150141415A1 (en) | 2013-11-20 | 2015-05-21 | Omonike Arike Olaleye | Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases |
| CN103886415A (zh) | 2014-03-25 | 2014-06-25 | 北京蝶禾谊安信息技术有限公司 | 药品管理方法和装置 |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| KR102245345B1 (ko) | 2014-09-29 | 2021-04-28 | 조게닉스 인터내셔널 리미티드 | 의약품 배포 제어를 위한 제어 시스템 |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| CN115487313A (zh) | 2015-02-06 | 2022-12-20 | 马瑞纳斯制药公司 | 静脉内加奈索酮制剂及其用途 |
| JP6884703B2 (ja) | 2015-02-25 | 2021-06-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 障害を治療するための５ｈｔ作動薬 |
| US10292996B2 (en) | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| JP6668045B2 (ja) | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| LT3310362T (lt) | 2015-06-17 | 2019-11-11 | Univ Columbia | Deoksinukleozidų terapija, skirta ligoms, sukeltoms nesubalansuotų nukleotidų telkinių, įskaitant mitochondrijų dnr išeikvojimo sindromą |
| KR102207539B1 (ko) | 2015-06-30 | 2021-01-26 | 네우라드 리미티드 | 신규한 호흡 제어 조절 화합물, 및 그의 제조 및 사용 방법 |
| US10004749B2 (en) | 2015-07-22 | 2018-06-26 | John Hsu | Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof |
| PT3340971T (pt) | 2015-08-24 | 2024-06-05 | Zogenix International Ltd | Métodos de tratamento da síndrome de lennox-gastaut com utilização de fenfluramina |
| US20220193082A1 (en) | 2015-09-14 | 2022-06-23 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| EP3170807B1 (en) | 2015-11-23 | 2019-12-11 | Frau Pharma S.r.l. | New method for synthesis of fenfluramine |
| KR102688278B1 (ko) | 2015-12-22 | 2024-07-26 | 조게닉스 인터내셔널 리미티드 | 펜플루라민 조성물 및 그 제조 방법 |
| JP2019507111A (ja) | 2015-12-22 | 2019-03-14 | ゾゲニクス インターナショナル リミテッド | 代謝抵抗性フェンフルラミン類縁体およびその使用法 |
| JP6753418B2 (ja) | 2016-01-14 | 2020-09-09 | Ａｇｃ株式会社 | フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品 |
| US20190083425A1 (en) | 2016-08-24 | 2019-03-21 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht2b agonists and methods of using same |
| CA3032996C (en) | 2016-08-24 | 2025-05-06 | Zogenix International Ltd | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| US20180092864A1 (en) | 2016-09-30 | 2018-04-05 | Zogenix International Limited | Compositions and methods for treating seizure disorders |
| BR112019023483A2 (pt) | 2017-05-09 | 2020-06-30 | Zogenix International Limited | composição farmacêutica para uso no tratamento, na prevenção e/ou no melhoramento dos sintomas da síndrome de doose, e, kit para tratar, prevenir e/ou melhorar um sintoma da síndrome de doose |
| US20190091179A1 (en) | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| WO2019067413A1 (en) | 2017-09-26 | 2019-04-04 | Zogenix International Limited | USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS |
| US20190247333A1 (en) | 2017-09-26 | 2019-08-15 | Zogenix International Limited | Method of reduction in convulsive seizure frequency |
| US20190091173A1 (en) | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Method of increasing time between convulsive seizures |
| US11352882B2 (en) | 2018-03-12 | 2022-06-07 | Cameron International Corporation | Plug assembly for a mineral extraction system |
| AU2019255745A1 (en) | 2018-04-18 | 2020-11-19 | The Trustees Of Columbia University In The City Of New York | Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes |
| CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| WO2019241005A1 (en) | 2018-06-14 | 2019-12-19 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| EP3820459A1 (en) | 2018-07-10 | 2021-05-19 | Zogenix International Limited | Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension |
| JP2021530541A (ja) | 2018-07-27 | 2021-11-11 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | てんかんの治療方法 |
| AU2019384963B2 (en) | 2018-11-19 | 2022-05-26 | Zogenix International Limited | Methods of treating Rett syndrome using fenfluramine |
| WO2020112460A1 (en) | 2018-11-30 | 2020-06-04 | Zogenix International Limited | A method of treating refractory epilepsy syndromes using fenfluramine enantiomers |
| EP3930841A4 (en) | 2019-02-25 | 2022-11-30 | Zogenix International Limited | A formulation for improving seizure control |
| US20210299064A1 (en) | 2020-02-05 | 2021-09-30 | Zogenix International Limited | Method of treating patients with lennox-gastaut syndrome |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20220096514A1 (en) | 2020-09-29 | 2022-03-31 | Zogenix International Limited | Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine |
-
2016
- 2016-12-20 JP JP2018532741A patent/JP2019507111A/ja active Pending
- 2016-12-20 US US15/385,512 patent/US20170174614A1/en not_active Abandoned
- 2016-12-20 KR KR1020187020704A patent/KR20180095674A/ko not_active Withdrawn
- 2016-12-20 WO PCT/US2016/067852 patent/WO2017112701A1/en not_active Ceased
- 2016-12-20 US US16/064,377 patent/US10689324B2/en active Active
- 2016-12-20 EP EP16879989.8A patent/EP3393470B1/en active Active
- 2016-12-20 CA CA3007673A patent/CA3007673A1/en active Pending
- 2016-12-20 AU AU2016379345A patent/AU2016379345B2/en active Active
-
2020
- 2020-05-08 US US16/870,128 patent/US11325882B2/en active Active
-
2022
- 2022-04-05 US US17/713,446 patent/US11673852B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3117160A (en) * | 1961-07-27 | 1964-01-07 | Pfizer & Co C | Aralkylamines |
| GB1399015A (en) * | 1971-08-28 | 1975-06-25 | Degussa | Fluoroalkylated phenylethylamine derivatives |
| JPH09501429A (ja) * | 1993-08-06 | 1997-02-10 | ジ・アップジョン・カンパニー | 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類 |
| JPH10501230A (ja) * | 1994-05-27 | 1998-02-03 | シンテックス（ユー・エス・エイ）インコーポレイテッド | １−ブチル−２−［２’−（２ｈ−テトラゾル−５−イル）−ビフェニル−４−イルメチル］−１ｈ−インドール−３−カルボン酸の製法 |
| WO2007073503A2 (en) * | 2005-12-21 | 2007-06-28 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| US20140142140A1 (en) * | 2011-07-08 | 2014-05-22 | Gosforth Centre (Holdings) Pty Ltd | Pharmaceutical composition for neurological disorders |
Non-Patent Citations (3)
| Title |
|---|
| EPILEPSIA, vol. 53(7), JPN6020043327, 2012, pages 1131 - 1139, ISSN: 0004384706 * |
| PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, vol. 59(3), JPN6020043328, 1998, pages 709 - 715, ISSN: 0004384707 * |
| REGISTRY(STN)[ONLINE], JPN6020043329, ISSN: 0004384708 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3393470A1 (en) | 2018-10-31 |
| US20190002391A1 (en) | 2019-01-03 |
| AU2016379345B2 (en) | 2020-09-17 |
| US11325882B2 (en) | 2022-05-10 |
| US20170174614A1 (en) | 2017-06-22 |
| US10689324B2 (en) | 2020-06-23 |
| EP3393470A4 (en) | 2019-05-08 |
| AU2016379345A1 (en) | 2018-06-14 |
| WO2017112701A1 (en) | 2017-06-29 |
| US20200331844A1 (en) | 2020-10-22 |
| EP3393470B1 (en) | 2021-01-20 |
| US20220289663A1 (en) | 2022-09-15 |
| CA3007673A1 (en) | 2017-06-29 |
| US11673852B2 (en) | 2023-06-13 |
| KR20180095674A (ko) | 2018-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11673852B2 (en) | Metabolism resistant fenfluramine analogs and methods of using the same | |
| KR101991326B1 (ko) | 오피오이드 수용체 리간드와 그 용도 및 제조방법 | |
| EP2774914B1 (en) | N-benzylaniline derivative and uses thereof | |
| TWI396532B (zh) | 用視黃基衍生物治療眼疾之方法及組合物 | |
| US12378193B2 (en) | Anti-arrhythmicity agents | |
| JP6661533B2 (ja) | ミトコンドリアを標的とするジカルボニル捕捉化合物 | |
| CN112739346A (zh) | 大麻素及其用途 | |
| JP7219387B1 (ja) | ４－（２，４－ジフルオロフェニル）－２－（１ｈ－インドール－３－イル）－４－オキソ－ブタン酸のｒ体 | |
| JP2023523051A (ja) | 脂質代謝関連疾患の予防又は治療用化合物 | |
| WO2017197324A1 (en) | Adrenergic receptor modulating compounds and methods of using the same | |
| JP5733839B2 (ja) | 神経変性疾患治療薬 | |
| JP2014514259A (ja) | 疼痛および他の障害の処置のための化合物および方法 | |
| JP6958860B2 (ja) | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 | |
| US20030171379A1 (en) | Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds | |
| CN115463218B (zh) | Shh通路调控生物节律及其相关应用 | |
| JP2022554159A (ja) | Ｇａｂａａ受容体モジュレーターによるてんかん状態の治療 | |
| US20170296681A1 (en) | Compositions and methods for imaging | |
| KR20190058494A (ko) | 모낭 줄기 세포 활성화 및 모발 성장 | |
| US20170197897A1 (en) | Skin Lightening Compounds | |
| AU2024225907A1 (en) | Hydroxyalkyl and methoxyalkyl tryptamines | |
| WO2025079163A1 (ja) | ４－（２，４－ジフルオロフェニル）－２－（１ｈ－インドール－３－イル）－４－オキソ－ブタン酸のｓ（＋）体 | |
| HK40016699B (zh) | 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法 | |
| US20030166516A1 (en) | Methods of treating, preventing, or inhibiting inflammation with exumolide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191210 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191210 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201022 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201218 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210526 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210630 |